Navigation Links
SleepQuest Compliance Again Doubles Industry Average
Date:2/3/2009

Study Shows Patients Consistently Adhere to Sleep Apnea Treatment

SAN CARLOS, Calif., Feb. 3 /PRNewswire/ -- SleepQuest announced today that an internal study has shown their patients comply with Obstructive Sleep Apnea treatment at a rate nearly twice the industry average.

Analysis performed in October 2008 looked at Northern California patients who received home sleep testing and treatment with Positive Airway Pressure beginning in early 2008. Of the patients surveyed, 91% were compliant, while known industry standards are closer to 50%. This percentage is based on the average number of treatment hours for patients using CPAP more than four hours per night.

"Compliance is dependent upon the caregiver's expertise with the many different complications that might occur with PAP treatment," said Robert Koenigsberg, SleepQuest President/CEO. "Our resolute focus is to troubleshoot problems that patients may experience and to find the right solutions for them."

Obstructive Sleep Apnea (OSA) is a dangerous condition in which soft tissues in the throat collapse during sleep, triggering a partial awakening to prevent suffocation. During PAP treatment (Continuous, Bi-level and AutoPAP), the patient receives positive air flow via a mask or nasal interface that keeps the airway open, allowing regular, quiet breathing and restful sleep to occur. Patients frequently have a hard time adjusting to treatment. Trial and error is often required to find the right combination of facial interface type, the most appropriate PAP device, and air flow settings that are most comfortable. If patients find it unpleasant, difficult to operate, or ineffective, they may lose interest in adhering to treatment.

"Most providers of CPAP therapy are general home care companies," said Lori Schulman, SleepQuest's Director of Contracting. "They focus on providing 1500 different products aimed at 150 different dise
'/>"/>

SOURCE SleepQuest
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SleepQuest Achieves Coveted Accreditation
2. SleepQuest Tireless in Pursuit of Good Sleep
3. Latest Sleep Disorder Technology Tested With SleepQuest
4. SleepQuest to Open San Francisco Office
5. SleepQuest Raises Awareness of Sleep Disorders
6. SleepQuest Launches Updated Web Site
7. Level 3 Inspection Achieves 100% Compliance in ISO 9001 & AS 9100 Certification
8. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
11. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... 20, 2014  GenVec, Inc. (NASDAQ: GNVC ) ... Ph.D., from its board of directors effective on October 24, ... and served as its chairman from June 2006 to November ... and Corporate Governance and Audit Committees of the board.  ... decade of dedicated service to GenVec, and its stockholders," said ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... (bortezomib) for Injection sales surpassed $765 ... million in 2007 - - VELCADE ... myeloma, with launch on track for first half of ... ) today reported 2007 non-GAAP net,income of $86.9 million and GAAP net income ...
... under European Accelerated Assessment Procedure, BOULDER, ... PHRM ) today announced that the European ... Company,s Marketing Authorization Application,(MAA) for Vidaza(R) (azacitidine ... (MDS) and announced its intent to,review the ...
... Continues to Lead Tropism Testing Field, SOUTH ... (Nasdaq: MGRM ) today announced that data ... been presented as multiple,posters during the 15th Conference ... Boston, MA. Highlights from the meeting,include data on ...
Cached Biology Technology:Millennium Over-Delivers on 2007 Goals and Financial Guidance 2Millennium Over-Delivers on 2007 Goals and Financial Guidance 3Millennium Over-Delivers on 2007 Goals and Financial Guidance 4Millennium Over-Delivers on 2007 Goals and Financial Guidance 5Millennium Over-Delivers on 2007 Goals and Financial Guidance 6Millennium Over-Delivers on 2007 Goals and Financial Guidance 7Millennium Over-Delivers on 2007 Goals and Financial Guidance 8Millennium Over-Delivers on 2007 Goals and Financial Guidance 9Millennium Over-Delivers on 2007 Goals and Financial Guidance 10Millennium Over-Delivers on 2007 Goals and Financial Guidance 11Millennium Over-Delivers on 2007 Goals and Financial Guidance 12Millennium Over-Delivers on 2007 Goals and Financial Guidance 13Millennium Over-Delivers on 2007 Goals and Financial Guidance 14Millennium Over-Delivers on 2007 Goals and Financial Guidance 15Millennium Over-Delivers on 2007 Goals and Financial Guidance 16Millennium Over-Delivers on 2007 Goals and Financial Guidance 17Millennium Over-Delivers on 2007 Goals and Financial Guidance 18EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes 2EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes 3EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes 4EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes 5Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity 2Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity 3Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity 4Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity 5Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity 6
(Date:10/16/2014)... Washington land managers have a new synthesis of recent ... mixed-conifer (MMC) forests in the two states. , ... Eastern Oregon and Washington: A Synthesis of the Relevant ... general technical report published by the U.S. Forest Service,s ... a request from managers for a synthesis of the ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... Chase, MD Maintaining adequate levels of vitamin D can help ... according to a recent study accepted for publication in The ... ( JCEM ). The study of more than 10,000 ... absorbed more vitamin D into their bodies. Vitamin D is ...
... NY) Researchers at Albert Einstein College of ... strategy for preventing infections due to the highly common ... herpes (herpes simplex virus 2) and cold sores (herpes ... The FASEB Journal , could lead to new drugs ...
... nature reserves and wetlands of the semi-arid wheatbelt of ... fauna are the backdrop for new research to improve ... The project will combine the latest ideas ... the pioneering ambitions of forward-thinking Australian environmental planners. ...
Cached Biology News:Vitamin D benefits breathing in tuberculosis patients 2Einstein study reveals new approach for stopping herpes infections 2Nottingham-Australia collaboration on environmental conservation of the future 2Nottingham-Australia collaboration on environmental conservation of the future 3
... Ascent is the first nephelometer ... microplates. Nepheloskan measures light scattering ... for particle quantification. This makes ... in drug discovery, immunoprecipitation, and ...
... Form: White powder Assay: 1.5 - 2.0 Bleomycin units/mg Identity ... On Drying: less than or equal to 6.0% Copper (Cu): ... : 55 - 70% B 2 : 25 - 32% ... to 90% B 4 : less than or equal to ...
... deliver critical performance for all vacuum requirements. ... pump performance to suit all applications. The ... checking of proper oil levels at a ... designed to work with all Thermo Savant ...
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
Biology Products: